Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | LIPC | P11150 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118235 | 0.89 | DHODH (0.37) | DHODHROCK2MAPK14 | |
| SCHEMBL3652596 | 0.88 | CACNA1G (0.34) | ROCK2PDE10A | |
| SCHEMBL4135549 | 0.88 | DHODH (0.36) | DHODHROCK2HDAC3HDAC4HDAC6 | |
| SCHEMBL4138886 | 0.87 | DHODH (0.32) | DHODHROCK2HDAC3HDAC4HDAC6 | |
| SCHEMBL3653706 | 0.87 | DHODH (0.32) | DHODHROCK2PTGDR2 | |
| SCHEMBL4137738 | 0.84 | EDNRA (0.37) | PTGDR2MAPK14 | |
| SCHEMBL3653891 | 0.84 | ALDH1A1 (0.36) | ROCK2PTGDR2 | |
| SCHEMBL4119012 | 0.83 | LIPG (0.32) | DHODHLIPCLIPG | |
| SCHEMBL4123415 | 0.83 | MAPK14 (0.34) | DHODHROCK2PTGDR2MAPK14LIPC | |
| SCHEMBL3653705 | 0.81 | DHODH (0.33) | DHODHROCK2PTGDR2MAPK14LIPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | DHODH 1560/4885ROCK2 2658/4885PTGDR2 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.